Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification
Clinics in Liver Disease · 2026-05 · 30 (2) · 359-379
DOI: 10.1016/j.cld.2026.01.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2026-05. Verfasst von Dana Ivancovsky-Wajcman und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Global NASH/MASH Council, Washington, DC, USA. Electronic address: danaivanc@gmail.com. Hauptthemen laut MEDLINE: Life Style, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit nennt 57 Literaturangaben.
Abstract (Originalsprache)
Weight reduction (≥5% to improve steatosis and ≥7-10% to improve inflammation and fibrosis) through lifestyle modifications is a first-line treatment of metabolic dysfunction-associated steatotic liver disease. Although the Mediterranean diet is the most evidence-based and recommended diet, similar plant-based diets are also acceptable. Physical activity and exercise (aerobic and resistance) are effective in steatosis reduction, independent of weight loss. However, the uptake of lifestyle interventions is challenging, and to enhance adherence, clinicians, policymakers, and stakeholders should support individuals by increasing awareness and promoting a healthier environment. Behavioral support, personalization, and sustainability of recommendations are key factors in individualized treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Global NASH/MASH Council, Washington, DC, USA. Electronic address: danaivanc@gmail.com.
- The Global NASH/MASH Council, Washington, DC, USA.
- The Global NASH/MASH Council, Washington, DC, USA; School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.
Zitieren
APA
Ivancovsky-Wajcman, D., Pekas, E. J., de Avila, L., Gerber, L. H., & Zelber-Sagi, S. (2026). Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification. Clinics in Liver Disease, 30(2), 359-379. https://doi.org/10.1016/j.cld.2026.01.002
Vancouver
Ivancovsky-Wajcman D, Pekas EJ, de Avila L, Gerber LH, Zelber-Sagi S. Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification. Clinics in Liver Disease. 2026;30(2):359-379. doi:10.1016/j.cld.2026.01.002
BibTeX
@article{IvancovskyWajcman2026,
author = {Ivancovsky-Wajcman, Dana and Pekas, Elizabeth J and de Avila, Leyla and Gerber, Lynn H and Zelber-Sagi, Shira},
title = {Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification},
journal = {Clinics in Liver Disease},
year = {2026},
volume = {30},
number = {2},
pages = {359--379},
doi = {10.1016/j.cld.2026.01.002}
}
EUVIMED